1 Center for Diabetes Technology, Department of Medicine, University of Virginia.
2 John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts.
Diabetes Technol Ther. 2019 Feb;21(2):73-80. doi: 10.1089/dia.2018.0308. Epub 2019 Jan 16.
Use of artificial pancreas (AP) requires seamless interaction of device components, such as continuous glucose monitor (CGM), insulin pump, and control algorithm. Mobile AP configurations also include a smartphone as computational hub and gateway to cloud applications (e.g., remote monitoring and data review and analysis). This International Diabetes Closed-Loop study was designed to demonstrate and evaluate the operation of the inControl AP using different CGMs and pump modalities without changes to the user interface, user experience, and underlying controller.
Forty-three patients with type 1 diabetes (T1D) were enrolled at 10 clinical centers (7 United States, 3 Europe) and 41 were included in the analyses (39% female, >95% non-Hispanic white, median T1D duration 16 years, median HbA1c 7.4%). Two CGMs and two insulin pumps were tested by different study participants/sites using the same system hub (a smartphone) during 2 weeks of in-home use.
The major difference between the system components was the stability of their wireless connections with the smartphone. The two sensors achieved similar rates of connectivity as measured by percentage time in closed loop (75% and 75%); however, the two pumps had markedly different closed-loop adherence (66% vs. 87%). When connected, all system configurations achieved similar glycemic outcomes on AP control (73% [mean] time in range: 70-180 mg/dL, and 1.7% [median] time <70 mg/dL).
CGMs and insulin pumps can be interchangeable in the same Mobile AP system, as long as these devices achieve certain levels of reliability and wireless connection stability.
使用人工胰腺(AP)需要设备组件的无缝交互,例如连续血糖监测仪(CGM)、胰岛素泵和控制算法。移动 AP 配置还包括智能手机作为计算中心和云应用程序(例如远程监控和数据审查和分析)的网关。这项国际糖尿病闭环研究旨在展示和评估使用不同 CGM 和泵模式的 inControl AP 的操作,而无需更改用户界面、用户体验和底层控制器。
43 名 1 型糖尿病(T1D)患者在 10 个临床中心(7 个在美国,3 个在欧洲)入组,41 名患者纳入分析(女性占 39%,>95%非西班牙裔白人,T1D 病程中位数为 16 年,HbA1c 中位数为 7.4%)。不同的研究参与者/地点使用相同的系统集线器(智能手机)在 2 周的家庭使用中测试了两种 CGM 和两种胰岛素泵。
系统组件之间的主要区别在于它们与智能手机的无线连接的稳定性。两种传感器的连接率相似,通过闭环时间的百分比来衡量(75%和 75%);然而,两种泵的闭环依从性有明显差异(66%对 87%)。当连接时,所有系统配置在 AP 控制下都实现了相似的血糖结果(73%[平均]时间在范围内:70-180mg/dL,1.7%[中位数]时间<70mg/dL)。
只要这些设备达到一定的可靠性和无线连接稳定性,CGM 和胰岛素泵就可以在同一个移动 AP 系统中互换使用。